Total Payments
$155,850
2024 Payments
$7,000
Companies
20
Transactions
153
Medicare Patients
8,846
Medicare Billing
$389,299
Payment Breakdown by Category
Consulting$91,085 (58.4%)
Travel$31,731 (20.4%)
Research$16,171 (10.4%)
Other$12,388 (7.9%)
Food & Beverage$4,476 (2.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $91,085 | 28 | 58.4% |
| Travel and Lodging | $31,731 | 54 | 20.4% |
| Unspecified | $16,171 | 6 | 10.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,238 | 6 | 4.0% |
| Honoraria | $6,150 | 3 | 3.9% |
| Food and Beverage | $4,476 | 56 | 2.9% |
Payments by Type
General
$139,679
147 transactions
Research
$16,171
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $21,800 | 11 | $0 (2022) |
| PFIZER INC. | $19,132 | 5 | $0 (2022) |
| Eli Lilly and Company | $17,800 | 4 | $0 (2024) |
| Novo Nordisk Inc | $16,213 | 9 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $13,221 | 4 | $0 (2020) |
| Boehringer Ingelheim International GmbH | $12,474 | 7 | $0 (2023) |
| CSL Behring | $11,194 | 52 | $0 (2020) |
| CryoLife, Inc. | $7,842 | 20 | $0 (2020) |
| Artivion, Inc. | $6,631 | 3 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $6,597 | 9 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,000 | 2 | Eli Lilly and Company ($7,000) |
| 2023 | $17,728 | 16 | Eli Lilly and Company ($10,800) |
| 2022 | $7,956 | 4 | Artivion, Inc. ($3,256) |
| 2021 | $12,839 | 7 | AbbVie Inc. ($5,775) |
| 2020 | $14,767 | 10 | E.R. Squibb & Sons, L.L.C. ($4,550) |
| 2019 | $19,095 | 29 | AbbVie, Inc. ($7,363) |
| 2018 | $50,434 | 55 | PFIZER INTERNATIONAL LLC ($13,682) |
| 2017 | $26,032 | 30 | Novo Nordisk Inc ($7,016) |
All Payment Transactions
153 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 04/11/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,400.00 | General |
| 12/31/2023 | Boehringer Ingelheim International GmbH | TRADJENTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,327.31 | General |
| Category: DIABETES | ||||||
| 10/19/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 08/01/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $7,600.00 | General |
| 07/06/2023 | ATRICURE, INC. | SYNERGY ABLATION SYSTEM (Device) | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/08/2023 | Artivion, Inc. | ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER (Device) | Consulting Fee | Cash or cash equivalent | $3,375.00 | General |
| Category: Cardiovascular surgery | ||||||
| 04/23/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Travel and Lodging | In-kind items and services | $116.84 | General |
| 04/23/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $84.42 | General |
| 04/23/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $75.42 | General |
| 04/23/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $34.28 | General |
| 04/23/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $34.28 | General |
| 04/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 04/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $89.13 | General |
| 04/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $75.42 | General |
| 04/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $34.28 | General |
| 04/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $34.28 | General |
| 01/25/2023 | Boehringer Ingelheim International GmbH | TRADJENTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $397.21 | General |
| Category: DIABETES | ||||||
| 08/25/2022 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| 05/04/2022 | PFIZER INC. | ELIQUIS (Drug) | Honoraria | Cash or cash equivalent | $1,950.00 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/28/2022 | Artivion, Inc. | CRYOVALVE SG PULMONARY HUMAN HEART VALVE (Device) | Honoraria | Cash or cash equivalent | $3,200.00 | General |
| Category: Cardiovascular surgery | ||||||
| 03/31/2022 | Artivion, Inc. | CRYOVALVE SG PULMONARY HUMAN HEART VALVE (Device) | Travel and Lodging | Cash or cash equivalent | $55.96 | General |
| Category: Cardiovascular surgery | ||||||
| 11/12/2021 | Ferring International Center SA | — | Consulting Fee | Cash or cash equivalent | $2,308.00 | General |
| 09/09/2021 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $2,475.00 | General |
| 04/22/2021 | ABBVIE INC. | ANDROGEL (Drug) | — | Cash or cash equivalent | $550.00 | Research |
| Study: Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study • Category: ENDOCRINOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase III Acute Coronary Syndromes CAD APPRAISE 2 | E.R. Squibb & Sons, L.L.C. | $5,636 | 1 |
| M16-100 | AbbVie, Inc. | $4,063 | 2 |
| A Phase 3, Active Warfarin Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation | E.R. Squibb & Sons, L.L.C. | $3,035 | 1 |
| Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study | ABBVIE INC. | $550.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,080 | 2,201 | $706,747 | $105,070 |
| 2022 | 20 | 2,355 | 2,505 | $729,630 | $115,495 |
| 2021 | 21 | 2,287 | 2,422 | $584,145 | $92,103 |
| 2020 | 19 | 2,124 | 2,194 | $505,291 | $76,631 |
Total Patients
8,846
Total Services
9,322
Medicare Billing
$389,299
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 233 | 235 | $232,415 | $29,940 | 12.9% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 490 | 498 | $138,444 | $23,348 | 16.9% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 227 | 230 | $22,540 | $6,083 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 68 | $17,340 | $5,604 | 32.3% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 186 | 187 | $28,798 | $4,905 | 17.0% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2023 | 80 | 80 | $36,000 | $4,399 | 12.2% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 25 | 25 | $25,750 | $4,032 | 15.7% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 52 | 53 | $35,722 | $3,843 | 10.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 58 | $10,092 | $3,413 | 33.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 36 | $9,000 | $3,098 | 34.4% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 35 | 35 | $24,535 | $2,670 | 10.9% |
| 93356 | Heart muscle strain imaging | Facility | 2023 | 304 | 308 | $47,432 | $2,494 | 5.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 21 | 21 | $5,712 | $1,823 | 31.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 11 | 44 | $7,216 | $1,564 | 21.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,832 | $1,483 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 17 | 17 | $6,630 | $1,398 | 21.1% |
| 93350 | Ultrasound of heart during rest, exercise and/or drug-induced stress with report | Facility | 2023 | 28 | 28 | $15,204 | $1,241 | 8.2% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 28 | 30 | $10,500 | $982.86 | 9.4% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 36 | 44 | $7,480 | $774.85 | 10.4% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 19 | 19 | $3,914 | $706.01 | 18.0% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 29 | 29 | $2,784 | $504.02 | 18.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 31 | 31 | $6,727 | $265.75 | 4.0% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 41 | 45 | $4,860 | $227.64 | 4.7% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Facility | 2023 | 13 | 13 | $1,105 | $148.39 | 13.4% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 51 | 55 | $715.00 | $122.20 | 17.1% |
About John Alexander
John Alexander is a Cardiovascular Disease healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831282094.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Alexander has received a total of $155,850 in payments from pharmaceutical and medical device companies, with $7,000 received in 2024. These payments were reported across 153 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($91,085).
As a Medicare-enrolled provider, Alexander has provided services to 8,846 Medicare beneficiaries, totaling 9,322 services with total Medicare billing of $389,299. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Durham, NC
- Active Since 10/02/2006
- Last Updated 03/21/2013
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1831282094
Products in Payments
- ELIQUIS (Drug) $30,540
- Victoza (Drug) $16,213
- TRADJENTA (Drug) $12,474
- On-X (Device) $7,558
- Androgel (Drug) $6,950
- XARELTO (Drug) $6,632
- ON-X AORTIC HEART VALVE WITH CONFORM-X SEWING RING AND EXTENDED HOLDER (Device) $3,375
- CRYOVALVE SG PULMONARY HUMAN HEART VALVE (Device) $3,256
- SYNERGY ABLATION SYSTEM (Device) $1,125
- ANDROGEL (Drug) $550.00
- ATRICURE ATRICLIP LAA EXCLUSION (Device) $550.00
- BRILINTA (Drug) $46.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Durham
R. Williams, M.d, M.D
Cardiovascular Disease — Payments: $3.3M
Cardiovascular Disease $3.3M
Jonathan Piccini, M.d., M.h.s, M.D., M.H.S
Cardiovascular Disease — Payments: $1.3M
Cardiovascular Disease $1.3M
David Kong, M.d., A.m., D.m.t, M.D., A.M., D.M.T
Cardiovascular Disease — Payments: $576,585
Cardiovascular Disease $576,585
Adrian Hernandez, M.d, M.D
Cardiovascular Disease — Payments: $535,728
Cardiovascular Disease $535,728
Chris Granger, M.d, M.D
Cardiovascular Disease — Payments: $510,675
Cardiovascular Disease $510,675
Christopher Kontos, M.d, M.D
Cardiovascular Disease — Payments: $473,112
Cardiovascular Disease $473,112